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Abstract
Background
Chagas disease, caused by the protozoan Trypanosoma cruzi, is the leading cause of heart
failure in Latin America. The clinical treatment of Chagas disease is limited to two 60 year-
old drugs, nifurtimox and benznidazole, that have variable efficacy against different strains
of the parasite and may lead to severe side effects. CYP51 is an enzyme in the sterol bio-
synthesis pathway that has been exploited for the development of therapeutics for fungal
and parasitic infections. In a target-based drug discovery program guided by x-ray crystal-
lography, we identified the 4-aminopyridyl-based series of CYP51 inhibitors as being effica-
cious versus T.cruzi in vitro; two of the most potent leads, 9 and 12, have now been
evaluated for toxicity and efficacy in mice.
Methodology/Principal findings
Both acute and chronic animal models infected with wild type or transgenic T. cruzi strains
were evaluated. There was no evidence of toxicity in the 28-day dosing study of uninfected
animals, as judged by the monitoring of multiple serum and histological parameters. In two
acute models of Chagas disease, 9 and 12 drastically reduced parasitemia, increased sur-
vival of mice, and prevented liver and heart injury. None of the compounds produced long
term sterile cure. In the less severe acute model using the transgenic CL-Brenner strain of
T.cruzi, parasitemia relapsed upon drug withdrawal. In the chronic model, parasitemia fell
to a background level and, as evidenced by the bioluminescence detection of T. cruzi
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expressing the red-shifted luciferase marker, mice remained negative for 4 weeks after drug
withdrawal. Two immunosuppression cycles with cyclophosphamide were required to re-
activate the parasites. Although no sterile cure was achieved, the suppression of parasite-
mia in acutely infected mice resulted in drastically reduced inflammation in the heart.
Conclusions/Significance
The positive outcomes achieved in the absence of sterile cure suggest that the target prod-
uct profile in anti-Chagasic drug discovery should be revised in favor of safe re-administra-
tion of the medication during the lifespan of a Chagas disease patient. A medication that
reduces parasite burden may halt or slow progression of cardiomyopathy and therefore
improve both life expectancy and quality of life.
Author summary
Chagas disease is a parasitic disease caused by the Trypanosoma cruzi. The infection may
result in gastrointestinal manifestations and cardiomyopathy. Benznidazole, the current
treatment, has limited efficacy and often leads to serious side effects. Aiming to develop
new treatments, our group has identified new inhibitors that block the synthesis of para-
sitic lipids, resulting in parasite death. In this work, we evaluated the safety and efficacy of
two of these compounds, 9 and 12, in mouse models of T. cruzi infection. Both com-
pounds were well-tolerated by animals throughout the 28-day administration. In acutely
infected mice, the compounds drastically reduced bloodstream parasites and increased
survival. When treatment was initiated during the chronic phase, parasitemia dropped to
background levels and remained undetectable for 4 weeks after drug withdrawal; parasites
were re-activated by chemically-induced immunosuppression. Thus, the experimental
compounds tested in these studies had an acceptable safety profile, achieved a marked
reduction in parasite load and prevented heart injury due to inflammation, even in the
absence of sterile cure. We conclude that the development of non-toxic medications capa-
ble of slowing the progression of cardiomyopathy is a valuable treatment option for Cha-
gas disease patients because it could enhance the quality of life.
Introduction
Chagas disease afflicts about 7 million people in South and Central America [1], where it is the
leading cause of heart failure. More than 10,000 deaths are estimated to occur annually due to
this disease. Despite joint efforts in Latin America to eradicate the transmission of Trypano-
soma cruzi through screening of blood banks and control of triatomine vectors, Chagas disease
presents a risk to 70 million people living in endemic countries [1,2]. International travel,
infected blood transfusions, co-infection with HIV, mother to fetus transmission, and north-
ward migration of the “kissing bug” insect vector [3], all help to drive up the number of cases
and push the incidence outside its historic range. Chagas disease is now seen in Europe, North
America and Asia and seems set to become an urgent public health issues in countries far
beyond its focal source in South America [4,5]. An annual economic burden due to Chagas
disease, calculated by simulation models as overall cost, reaches 7.19 billion US dollars, largely
from the loss of productivity and premature mortality caused by cardiomyopathy [6,7].
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Human infections by T. cruzi result in a significant mortality rate in children in the acute
phase, or may lead to cardiomyopathy in chronically infected adults [8,9]. About 40% of
infected individuals develop chronic manifestations of the disease: ten percent of patients
develop gastrointestinal symptoms (e.g., mega colon and mega esophagus); and 30% of
patients develop cardiac disease characterized by cardiomyopathy, arrhythmias and interstitial
fibrosis accompanied by cardiac inflammation[9]. The clinical treatment of Chagas disease is
limited to two drugs: nifurtimox and benznidazole, developed about 60 years ago. Nifurtimox
is now discontinued in several countries [10,11], while benznidazole has been recently FDA-
approved only for use in children of 2 to 12 years old [12,13].
Both benznidazole and nifurtimox are about 80% effective in the acute stage of Chagas dis-
ease [14]. Limitations of current therapy include variable efficacy against T. cruzi of different
genetic backgrounds and elevated toxicity with severe side effects, including widespread der-
matitis, digestive intolerance, polyneuritis and bone marrow depression, leading to poor
patient compliance [10,11]. Both drugs are used in cases of new infections, congenital infec-
tions, reactivation and/or re-aggravation associated with immunosuppression and as a preven-
tive measure against laboratory accidents [8]. The efficacy of benznidazole against the more
prevalent chronic stage of Chagas dissease was investigated in the BENEFIT clinical trial
[15,16]—the first randomized, placebo controlled, clinical study on the effects of benznidazole
on the clinical progression of chronic Chagas disease patients with compromised cardiac func-
tion. Drug treatment led to a marked reduction of the circulating parasite load in patients
from Brazil (strain TcII) and Argentina and Bolivia (strains TcV and TcVI), but not in patients
from Colombia or El Salvador (strain TcI). In all cases, benznidazole failed to reduce cardiac
function deterioration when evaluated at the 5–7 year follow-up. [15]. These results suggest
that benznidazole has limited clinical utility in patients with moderate to advanced cardiac
compromise (class I or II heart failure, New York Heart Association terminology). However,
an important qualification is that previous observational, not randomized, studies [17] suggest
that the drug is effective in patients in the asymptomatic (indeterminate) stage or those with
incipient cardiac compromise. A combination of benznidazole with posaconazole in the treat-
ment of asymptomatic patients (the STOP-Chagas clinical trial) also showed no advantage
over benznidazole monotherapy, as judged by the PCR test alone. Clinical disease as evidenced
by decreased cardiac function or other cardiomyopathy signs were not assessed in this study
[18]. In either case, there is an urgent need for safer and more efficacious drugs and drug com-
binations to meet the etiological challenges of this complex disease.
As an alternative to the use of benznidazole in patients with chronic Chagas disease [19],
significant efforts have been made to repurpose antifungal azole drugs targeting sterol biosyn-
thesis. Among validated sterol biosynthetic targets, CYP51 is one of the most extensively
exploited for the development of new therapeutics for fungal and parasitic infections [20,21].
The CYP51 inhibitors posaconazole (Noxafil, Merck) and ravuconazole (E1224, Eisai, Tokyo),
which have undergone extensive pharmacological and toxicological optimization in antifungal
programs, have demonstrated efficacy and curative activity in animal models of Chagas disease
[22], and alleviated chronic Chagas disease in a patient with systemic lupus erythematosus
[23,24]. Both drugs have been tested in controlled clinical trials for Chagas disease [18,25,26].
The perceived inferiority of both drugs to the current standard-of-care drug, benznidazole,
[25,27] was due to their failure to produce sterile cure (PCR negative), and triggered discus-
sions in the Chagas research community about the validity of CYP51 as a target [28,29]. Two
concerns have been expressed: (i) differential activity of CYP51 inhibitors against different
strains of T. cruzi or between the replicative (amastigote) and non-replicative (trypomastigote)
stages of the parasite and (ii) the slow-acting mechanism of CYP51 versus fast-acting benzni-
dazole [28–30]. A third factor that may have affected the outcomes of the clinical trials is that
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the repurposed antifungal drugs, including posaconazole and ravuconazole, were not opti-
mized to target T. cruzi CYP51.
In parallel with the clinical trials, a number of laboratories pursued novel chemical scaffolds
specifically targeting T. cruzi CYP51 (reviewed in [21]). Using a target-based structure-aided
drug discovery approach, a 4-aminopyridyl-based scaffold was identified as efficacious and
further developed into a series of lead compounds active against T. cruzi both in vitro and in
vivo [31–37] (Fig 1). Two optimized leads of the series, 9 [37] and 12 [35] (Fig 1, compound
numbers correspond to those in the cited references), have now been evaluated for both toxic-
ity and parasitological cure in the acute and chronic animal models of T. cruzi infection.
Although a sterile cure was not achieved, 9 and 12 were proven safe for long term administra-
tion in mice and suppressed parasitemia in both the acute and chronic phases. In the acute
model, these lead compounds improved survival, protected mice from hepatic injury and
Fig 1. The 4-aminopyridyl-based lead compounds. The lead compounds optimized by the structure-aided
rational drug design guided by x-ray crystallography and efficacy in the in vitro and in vivo T. cruzi infection
models. Both compounds have EC50 in low nanomolar range against cultured amastigotes, are orally
bioavailable and decrease 99% parasitemia in mice after 4-day oral dosing [35,37].
https://doi.org/10.1371/journal.pntd.0006132.g001
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drastically reduced cardiac inflammation. In the chronic phase, these lead compounds pre-
vented spontaneous T. cruzi relapse for up to 4 weeks post-treatment.
Results
Toxicity evaluation in uninfected mice
The No Observed Adverse Effect Level (NOAEL), of 9 and 12 was evaluated according to the
Organization for Economic Cooperation and Development (OECD) guidelines. Escalating
doses of 12 were administered orally to male and female Swiss mice every hour; adverse effects
were observed only at concentrations higher than 300 mg/kg for male and 250 mg/kg for
female mice. Cumulative in vivo effects were analyzed using uninfected BALB/c male and
female mice treated with 9 or 12 at 25 mg/kg orally for up to 28 days, b.i.d. No adverse clinical
signs (such as ruffled fur, hunched posture, reduced mobility, or tremor) or alteration in gen-
eral health were observed in any of the mice. Blood was collected after the end of treatment
and serum was evaluated in a chemistry panel that included liver enzymes and markers of
renal function. No alteration of blood levels for alanine aminotransferase (ALT), aspartate
aminotransferase (AST), bilirubin (BIL), albumin (ALB), blood urea nitrogen (BUN) or creati-
nine (CRE) was detected after the course of treatment (Fig 2). Histological analysis of brain,
heart, liver, kidney, GI tract and lungs did not show any alteration of tissue morphology. The
weights of the animals remained steady throughout the treatment.
Effect of compounds on severe acute infections with the lethal T. cruzi Y
strain
Since no toxicity was detected in uninfected mice, we performed a 28-day oral treatment at 25
mg/kg of compounds in Swiss male mice infected with T. cruzi Y strain (104 inoculum), an
established model of acute infection recommended for drug screening and development by
the Fiocruz Program for Research and Technological Development on Chagas Disease (PIDC/
Fiocruz) and the Drugs for Neglected Diseases Initiative (DNDi) [38]. Treatment with 9 or 12
at 25 mg/kg significantly reduced parasitemia, reaching the minimum limit of detection by the
Pizzi-Brener method at 9 days post infection (dpi), with inhibition levels of 99.9% for 9 and
99.3% for 12. Parasitemia remained undetectable in the treated mice, while untreated and
vehicle-treated mice showed high parasitemia and all of these mice died by 18 dpi (Fig 3A).
While parasites were not detected, only 20% of the infected mice treated with 9 and 80% of the
infected mice treated with 12 survived the entire 30 day study (Fig 3B). 100% of benznidazole-
treated mice survived. All mice were euthanized at the end of treatment. Compared to the neg-
ative controls, treatment with the test compounds did provide partial protection and delayed
the death of the mice. Death of the treated animals in this model of acute disease with Y strain
parasites may be due to yet unknown T. cruzi Y strain-specific factor(s) that could interfere
with the compound effect in the infected mice. That effect with Y strain parasites was not seen
in uninfected animals or animals infected with T. cruzi CL-luc strain.
Upon study completion, mice were euthanized and serum was assessed for hepatic enzymes
and renal function markers (Fig 3C–3F). Data from the blood chemistry analysis showed that
T. cruzi Y infection induced elevated serum levels of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST), indicating infection-induced liver injury. The animals
treated with 9 or 12 had reduced levels of these enzymes when compared to untreated controls.
Urea and creatinine (CRE) levels, markers of renal function, were also analyzed; treated ani-
mals show normal levels similar to that of untreated controls, suggesting no renal toxicity was
caused by 9 or 12.
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PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006132 December 27, 2017 5 / 24
Fig 2. Cumulative in vivo effect of 9 and 12. No alteration in the liver (ALT, AST, BIL, ALB, ALP) or kidney (BUN, CRE)
markers were observed in the course of mice treated with 9 or 12 at 25 mg/kg, for 28 days, b.i.d. Treatment groups are
labeled along the x-axis by the gender/drug combination.
https://doi.org/10.1371/journal.pntd.0006132.g002
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Fig 3. The effects of 4-aminopyridyl lead compounds on mice with acute T. cruzi infection. (A) Parasitemia levels in Swiss
male mice infected with T. cruzi Y strain (104 inoculum) and treated for 28 days with 9 or 12 (25 mg/Kg) are undetectable. (B)
Survival curve shows partial protection and delayed death of mice treated with 9 and 12 (25 mg/Kg) in the acute phase of the
infection. (C-F) Biochemical analysis of serum from infected mice treated with 9 or 12 (25 mg/Kg) was comparable to serum from
unifected controls and shows normal levels of liver enzymes—alanine aminotransferase (ALT;C) and aspartate aminotransferase
(AST;D)–as well as the renal function markers—creatinine (CRE; E) and urea (F). dpi—days post infection. *Statistically significant
by t test, p0.05.
https://doi.org/10.1371/journal.pntd.0006132.g003
Positive treatment outcome without sterile cure
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Effect of 9 and 12 on less severe acute infections with the transgenic
CL-Brenner T. cruzi strain in mice
Given that neither 9 nor 12 produced sterile cure in the T. cruzi Y-infected animals, we next
evaluated their effect in a less severe acute model using the transgenic CL-Brenner T. cruzi
strain expressing “red-shifted” luciferase (CL-luc, a gift from Dr. John Kelly, UK). This strain
carries a stable bioluminescent marker, which allows one to detect live parasites in tissues of a
live mouse with a sensitivity limit exceeding that of the RT-PCR method for up to a year after
infection [39,40]. Since mice gender influences the level of infection [41,42], we used both
male and female mice for the 28 day b.i.d. treatment beginning 14 dpi. Males not treated with
experimental or reference compounds showed levels of parasitemia higher than females (Figs
4, 5 and 6).
As judged by the bioluminescence (Fig 4), the level of CL-luc T. cruzi infection markedly
decreased at 18 dpi, which corresponds to 4 days of treatment with the experimental or refer-
ence compounds, benznidazole or posaconazole. By 32 dpi (18 days of treatment), the parasite
bioluminescence in all treated mice was reduced to the background level, with the photon
count lower than that of the uninfected mice injected with luciferin. Both groups of negative
control mice, including a group of infected but untreated mice, as well as a group of infected
and vehicle-treated mice, had bioluminescence levels two orders of magnitude higher than the
uninfected control mice. This trend was maintained up to 49 dpi (7 days after the end of treat-
ment). However, by 53 dpi (11 days after the end of treatment) animals from the benznidazole
(male and female), 12 (female), and 9 (male and female) groups all showed resurgence of para-
sites (Figs 4, 5 and 6). Posaconazole treated mice showed resurgence of parasites at 67 dpi.
Fig 4. Monitoring parasitemia in acutely infected with T. cruzi CL-luc BALB/c mice over the course of
28-day treatment with 9 or 12. Bioluminescence levels of infected and treated animals are indistinguishable
from those of uninfected control groups between days 28 and 49 post-infection. Parasite relapse ocurred two
weeks after the end of treatment, with males eventually reaching bioluminescence levels similar to untreated
controls, while females display lower levels of parasitemia.
https://doi.org/10.1371/journal.pntd.0006132.g004
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Fig 5. Development of parasitemia in acutely infected mice after the 28-day course of treatment with 9 or 12. The
photon count values are displayed for each individual animal up to 81 dpi, showing progressive parasite relapse. Post-
treatment evolution of parasetimea in live animals is shown in Fig 6.
https://doi.org/10.1371/journal.pntd.0006132.g005
Positive treatment outcome without sterile cure
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Fig 6. Post-treatment evolution of parasitemia in acutely infected mice monitored by bioluminescence imaging of
live animals. Stochastic profile of T. cruzi infection is shown. Abbreviations are M—male, F—female, Bz—benznidazole,
Pos—posaconazole, Sol—solutol, 9 and 12 –lead compounds.
https://doi.org/10.1371/journal.pntd.0006132.g006
Positive treatment outcome without sterile cure
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By 81 dpi, the majority of the animals in the 9- and 12-treated groups were T. cruzi-positive
as indicated by bioluminescence. All animals in the male group treated with 9 showed parasite-
mia as high as untreated controls at 81 days post infection. Both compounds reduced the para-
site load in female mice, where bioluminescence levels were 10× lower than untreated controls
in 4 out of 5 mice for both compounds at 81 dpi, with one 9-treated female negative (Table 1).
Posaconazole reduced T. cruzi bioluminescence to undetectable levels in 1 out of 5 males and
2 out of 4 females, with the remaining mice showing reactivation of parasites. Posaconazole
markedly reduced parasite load compared to the untreated controls. Finally, benznidazole was
not able to suppress parasites in all the mice, with one female showing circulating parasites
after treatment withdrawal (Figs 4, 5 and 6, Table 1).
Ex vivo bioluminescence imaging of internal organs was performed at 81 dpi. As previously
described for this model [39,43], parasites were detected consistently in the gastro-intestinal
(GI) tract in all T. cruzi-positive mice (Figs 7 and 8). Moreover, bioluminescence above the
background level was also observed randomly in heart, skeletal muscles, liver and mesenteric
fat in T. cruzi-positive mice throughout the groups, suggesting a dynamic infection process
(Fig 7). Ex vivo quantification of the parasite burden in the organs analyzed (heart, liver, kid-
neys, lungs, spleen, gastro-intestinal tract, skeletal muscle and mesenteric fat) was consistent
with the whole-mouse imaging. One female mouse treated with benznidazole showed traces of
infection in the GI tract, while posaconazole-treated animals revealed T. cruzi in the GI tract
and lung. For the experimental inhibitors, no parasites were detected in two females treated
with 12 and one female treated with 9. All other animals in the 9- or 12-treated groups showed
T. cruzi bioluminescence in GI tract, liver, lung and mesenteric fat (Figs 7 and 8).
Histopathological analysis
Tissue architecture and inflammation in the heart was evaluated through conventional histol-
ogy and H&E staining from both lethal acute and bioluminescent models, with the levels of
inflammation being quantified using FIJI software [44]. Uninfected mice had normal cardiac
tissue, as expected (Fig 9D). T. cruzi infection in untreated mice resulted in marked inflamma-
tion in heart tissue with inflammatory infiltrates and interstitial fibrosis in both acute models
(Fig 9A and 9F). BALB/c mice infected with CL-luc showed mild cardiac inflammation when
compared to Swiss mice infected with T. cruzi Y strain; the latter showed levels of inflammation
Table 1. Parasite load on 81 day post-infection by the luminescence level.
Compound/vehicle Mice sex Photons/s/cm2
106
Photons/s/cm2
105
Negative
( uninfected)
-/- Male 5/5 0/5 0/5
-/- Female 3/5 2/5 0/5
-/solutol Male 5/5 0/5 0/5
-/solutol Female 4/5 1/5 0/5
BZ/solutol Male 0/5 0/5 5/5
BZ/solutol Female 1/5 0/5 4/5
POS/solutol Male 0/5 4/5 1/5
POS/solutol Female 0/4 2/4 2/4
9/solutol Male 5/5 0/5 0/5
9/solutol Female 1/5 3/5 1/5
12/solutol Female 1/5 4/5 0/5
BZ—benznidazole, POS—posaconazole
https://doi.org/10.1371/journal.pntd.0006132.t001
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Fig 7. Ex vivo bioluminescence imaging of the internal organs of chronically-infected mice. Gastro-
intestinal (GI) tract, heart (H), skeletal muscle (SkM), liver (Li), lung (Lu), spleen (Sp) and mesenteric fat (F) are
shown uniformly positioned on a petri dish surface as indicated in the top left image. Each group of mice is
represented by one image labeled with the animal gender, compound name and a number of T. cruzi-positive
animals in the group of five. Collectively, bioluminescence was detected in the GI of all T. cruzi-positive
animals and randomly in heart, skeletal muscle, liver and mesenteric fat. Animals in the 9- or 12-treated groups
showed T. cruzi bioluminescence in the GI tract, liver, lung and mesenteric fat. Bioluminescence was not
detected in one female treated with 9 and two females treated with 12. Quantitative analysis of all animals is
shown in Fig 8.
https://doi.org/10.1371/journal.pntd.0006132.g007
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at least 2× higher than the former and included the presence of amastigote nests, which were
not observed in BALB/c mice infected with CL-luc (Fig 9A, 9F, 9E and 9J). In both models,
mice treated with benznidazole (Fig 9B and 9G), 9 (Fig 9C and 9H), or 12 (Fig 9I) had normal
heart tissue, with a significant reduction of inflammatory cells (Fig 9E and 9J) compared to
vehicle treated controls, and no signs of interstitial fibrosis or amastigote nests, suggesting that
the reduction of parasite load induced by treatment with the CYP51 inhibitors improved car-
diac pathology, even without sterile cure.
Effect of compounds in chronic infection
Most patients in need of treatment are in the chronic phase of Chagas disease. In this later
stage, parasite load is low enough to require sensitive techniques for parasite detection [45]. To
recapitulate these conditions, we evaluated performance of 9 in a chronic mouse model.
Because males are more susceptible to infection than females, BALB/c males were infected
with T. cruzi CL-luc strain allowing highly sensitive bioluminescence detection. Following the
treatment scheme reported [46], the compounds were administered at 25 mg/kg for 28 days
starting at 126 dpi, when chronic infection was established and the parasite signal was consis-
tently detected. Similar to the acute model described above, T. cruzi bioluminescence levels
dropped soon after the start of treatment. After 28 days, all treated groups, including 9, showed
only background luminescence (Fig 10A–10C). Mice were then followed for 4 weeks after
compound administration had ceased. For up to 27 days post-treatment, groups treated with
posaconazole or 9 had bioluminescence levels slightly above the background defined by the
uninfected mice and 10–100× lower than the untreated controls (Fig 10D and 10E). Since the
parasite load was below the detection level 4 weeks post-treatment, the animals were immu-
nossupressed with cyclophosphamide. After 2 rounds of immunossupression, parasites
relapsed as evidenced by the bioluminescence levels similar to those of the untreated controls.
Discussion
A similarity in sterol biosynthesis pathways between T. cruzi and fungi is that both produce
ergosterol and ergosterol-like sterols as membrane building blocks [47]. This similarity
Fig 8. Quantitative analysis of ex vivo bioluminescence in the internal organs of chronically-infected
mice. Each animal is represented by an individual data point. Treatment groups are labeled along the x-axis
by the gender and drug name. (A) Cumulative signal from all the organs in each individual animal. (B) Signal
from the GI tract alone. The majority of the bioluminescent parasites are associated with the GI tract.
https://doi.org/10.1371/journal.pntd.0006132.g008
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Fig 9. Histopathological analysis of heart tissue. H&E staining of heart tissue from acute models of T.
cruzi infection. (A-D) BALB/c female mice infected with T. cruzi CL-luc. (F-I) Lethal infection of Swiss male
mice infected with T. cruzi Y strain. In F, the parasite nests are labeled with the asterisks. Bar = 100μM. (E, J)
Inflammation quantified using FIJI software.[44]. * Statistically significant by t test, p0.05.
https://doi.org/10.1371/journal.pntd.0006132.g009
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Fig 10. Effect of 4-aminopyridyl compounds in chronic infection. Parasite levels measured by
bioluminescence detection in BALB/c males infected with T. cruzi CL-luc strain. (A) Average levels from all
groups from 102 to 197 dpi. Individual values for each mouse in the groups represented separately on 123 dpi
(B), 151 dpi (C), 179 dpi (D) and 197 dpi (E).
https://doi.org/10.1371/journal.pntd.0006132.g010
Positive treatment outcome without sterile cure
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encouraged the application of antifungal drugs for the treatment of Chagas disease. However,
in human clinical trials for Chagas disease, both posaconazole and ravuconazole failed to dem-
onstrate superiority to the current standard-of-care drug, benznidazole, using PCR as a marker
of continued or reactivated T.cruzi infection [25,27]. The failure of posaconazole and ravuco-
nazole to attain sterile cure in humans raised concerns about the CYP51 target. Differential
activity of CYP51 inhibitors against the replicative (amastigote) and non-replicative (trypo-
mastigote) stages of T. cruzi, a slow-acting mechanism of action, and the stochastic nature of
T. cruzi infection with the non-replicating or rarely-replicating cryptic amastigotes ‘hidden’
inside the tissues [39], were listed as potential drawbacks of the CYP51 target [28,48]. On the
other hand, it has been argued that both the dose and the duration of anti-fungal agents used
in the clinical trials to treat human T. cruzi infection have been suboptimal. Urbina et al. noted
that the plasma exposure in patients for the dose used in clinical trials corresponds to 10–20%
of the curative dose in mice [29,49]. The post-clinical trial tendency to balance risks in the
Chagas drug discovery portfolio, and to identify drug candidates aimed at other molecular tar-
gets is logical. At the same time, it is critical to not reject promising targets based on clinical
studies with drugs not properly optimized, dosed, or clinically evaluated.
An important, but overlooked factor, that may have affected the performance of the anti-
fungal drugs in Chagasic patients, is the loose drug-target fit demonstrated by posaconazole in
co-crystal structures with Trypanosome CYP51. The electron density of the bound drug is
poorly defined and its pendant phenyl-2-hydroxy-pentantriazolone group adopts alternative
conformations to make multiple interactions outside of the active site [50,51]. Several novel
CYP51 inhibitors developed in this collaboration [33–37] and elsewhere [51–53] demonstrated
drug-target fits superior to posaconazole. The most potent 4-aminopyridyl-based inhibitors of
the 4-aminopyridyl-based series bind entirely in the CYP51 target interior, making tight inter-
actions with hydrophobic residues constituting the CYP51 active site [35,37]. Improved drug-
target interactions may be responsible, at least in part, for the superior potency of the experi-
mental inhibitors in the acute and chronic mouse models of infection [54].
Neither of the two lead compounds of the 4-aminopyridyl-based series evaluated in these
studies attained a sterile cure. However, both leads were proven safe for long term administra-
tion in mice and, efficiently suppressed parasitemia in both acute and chronic models of
infection. In the acute phase, compounds improved survival in highly stringent acute mouse
models, protected mice from hepatic injury, and drastically reduced acute cardiac inflamma-
tion. In a model of chronic Chagas disease, 9 prevented spontaneous T. cruzi relapse for up to
4 weeks post-treatment. Similar results—supression of parasitemia, no spontaneous relapse
after treatment withdrawal and parasite reactivation after immunossupression—were also
achieved by other research groups using CYP51 inhibitors based on different molecular scaf-
folds [41,46,55].
Collectively, 9 is more efficacious in the treatment of the chronic phase of the disease with
low parasite load. Although 9 did not eradicate cryptic reservoirs of parasites in vivo after 28
days of treatment, it successfully kept parasites under control and prevented the inflammation
responsible, in part, for cardiac tissue damage. This outcome is not unique for inhibitors that
target the ergosterol synthesis pathway. Treatment of chronically infected mice with N,N-
dimethylsphingosine, an inhibitor of sphingosine kinase, also failed to produce a sterile cure,
but reduced parasite load leading to a marked decrease in inflammation and fibrosis. Further-
more, there was a reduction of inflammatory mediators and an improvement of heart function
measured as exercise capacity [56]. In addition, mice infected with resistant strains of T. cruzi
showed decreased tissue parasitemia, reduced myocarditis and less electrocardiographical
alterations after treatment with benznidazole, even though the drug failed to completely elimi-
nate parasites in this model [57].
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Several mechanisms have been proposed to explain the pathogenesis of Chagas’ cardiomy-
opathy, including parasite-dependent inflammation, autoimmunity, autonomic neuronal
degeneration and damage of microvasculature [58,59]. Although more than one mechanism
may be involved in Chagas disease pathogenesis, a consensus is that tissue damage is related
to parasite persistence [58–60]. At the same time, 60–70% of infected individuals are asymp-
tomatic. A balance between host and parasite in asymptomatic cases may be maintained by
expression of the anti-inflammatory cytokine IL-10, while cardiomyopathy is associated with
inflammation triggered by IFN-gamma and TNF-alpha [61]. Reducing the parasite burden
diminishes inflammation even without complete elimination of the parasite [60]. In this
regard, several non-randomized clinical trials have shown that etiological treatment of chronic
patients with benznidazole resulted in slower progression to advanced stages of cardiomyopa-
thy evaluated by electrocardiography and echocardiography [17,62].
Sterile cure is a highly desirable treatment outcome, however, it may not always be
achieved, and drug discovery efforts are often hampered by deficiencies in understanding the
nuances of disease pathogenesis. There is currently no sterile cure of HIV infection. The desir-
able outcome of the antiretroviral treatment is a long term plasma HIV-RNA count below 50
copies/ml [63]. The WHO recommends antiretrovirals in people of all ages, including preg-
nant women as soon as the diagnosis is made; once treatment is begun, it is recommended to
continue throughout the entire life span without interruptions [63]. Benefits of treatment
include a decreased risk of progression to AIDS and a decreased risk of death [64]. Highly
active antiviral therapy options are available as drug ‘cocktails’ consisting of at least three med-
ications belonging to at least two different classes of antiviral agents [65]. As of 2017, 19.5 mil-
lion people are accessing antiretroviral therapy and more than half of all people living with
HIV are on treatment [66].
By analogy with HIV/AIDS, the treatment option of non-toxic medications should be
developed for Chagas patients to slow down progression to cardiomyopathy and to improve
life expectancy and quality of life. With the scarce arsenal of anti-T. cruzi agents, the drug dis-
covery community cannot afford to be prejudiced against CYP51, or any other target, if the
inhibitors have acceptable safety profiles and achieve a marked reduction in parasite load, even
in the absence of sterile cure. Regardless of the molecular target affected by the drug, develop-
ment of an efficacious and safe treatment for Chagas disease would be a breakthrough for soci-
ety, medicine and science.
Material and methods
Ethics statement
Research performed at UC San Diego was conducted in compliance with the Animal Welfare
Act and other federal statutes and regulations relating to animals and experiments involving
animals and adheres to the principles stated in the Guide for the Care and Use of Laboratory
Animals, National Research Council, 2011. The facility where this research was conducted is
fully accredited by the Association for Assessment and Accreditation of Laboratory Animal
Care International. Animal research was conducted under approved protocol S14187 from the
Institutional Animal Care and Use Committee, University of California, San Diego. Research
performed at Oswaldo Cruz Foundation—FIOCRUZ, Rio de Janeiro, Brazil, was approved by
the Committee for Ethics in the Use of Animals of FIOCRUZ, under protocol number LW-
37/13 and is in compliance with Brazilian Federal Law number 11794/08, Federal Brazilian
Decree number 6899/09 and Brazilian Normative Resolution number 1 (July 9th, 2010) of the
National Council for the Control of Animal Experimentation. Euthanasia was accomplished
by CO2 inhalation or by sodium pentobarbital overdose (60 mg/kg), followed by cervical
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dislocation. These methods of euthanasia have been selected because they cause minimal pain
and distress to animals, are relatively quick, and do not adversely impact interpretation of the
results of studies. All methods are in accord with the recommendations of the Panel on Eutha-
nasia of the American Veterinary Medical Association.
Materials
Compounds 9 and 12 were synthesized by following the procedures previously reported [35,37].
Animals
In vivo experiments were performed at the University of California San Diego (UCSD), La
Jolla, California, USA and Oswaldo Cruz Foundation—FIOCRUZ, Rio de Janeiro, Brazil. At
FIOCRUZ, Swiss Webster male and female mice weighting 18–20 g were obtained from
CEMIB (Centro Multidisciplinar para Investigac¸ão Biolo´gica), UNICAMP (Campinas, SP,
Brazil). At UCSD, male and female 6 weeks old BALB/c mice, in the same weight range, were
purchased from Jackson Laboratories (Farmington, CT, USA). Mice were housed in a maxi-
mum number of 5 animals per cage and kept in a conventional room at 20 to 24˚C under a 12
h/12 h light/dark cycle. The animals were provided with sterilized water and chow ad libitum.
Toxicity assays
Acute toxicity was evaluated by administration of escalating doses of the compounds to male
and female Swiss Webster mice (n = 2/group) orally by gavage, at 100 ul/hour 50 mg/kg dose
formulated in 20% solutol (also known as Kolliphor HS15) (Sigma #42966). The general health
of the animals was closely monitored for up to 48 h and the last dose before the onset of toxic
symptoms were observed was defined as NOAEL according to the OECD guidelines. Cumula-
tive toxicity after prolonged treatment was evaluated using BALB/c females (n = 5/group)
treated orally by gavage with the experimental CYP51 inhibitors, 9 (25 mg/kg) or 12 (25 mg/
kg), dissolved in 10% solutol, at 100 ul/dose, b.i.d, for 28 consecutive days. Mice were weighed
once a week and their general health was assessed daily. After treatment, mice were eutha-
nized, blood was collected for analysis of several biochemical markers of general health. Brain,
heart, liver, kidney, gastro-intestinal (GI) tract and lungs were collected, briefly rinsed in PBS
and fixed in buffered formalin solution including 10% formaldehyde, 33 mM NaH2PO4, 45
mM Na2HPO4 for histological evaluation.
Parasites
The T. cruzi Y parasites were obtained from the bloodstream of infected Swiss Webster mice at
the peak of parasitemia, as previously described [67]. Transgenic T. cruzi CL Brener parasites
expressing a red-shifted luciferase that emits light in the tissue-penetrating orange-red region
of the spectrum (a gift from Dr. John Kelly, London School of Hygiene and Tropical Medicine,
London, United Kingdom), were obtained as described previously [39]. Epimastigote forms
were maintained at 28˚C in LIT media supplemented with 10% FBS and 100 μg/ml of antibi-
otic G418 to keep selective pressure in favor of the luciferase marker [68]. Epimastigotes were
induced to differentiate to trypomastigotes through metacyclogenesis as previously described
[69]. Metacyclic trypomastigotes were used to infect C2C12 myoblasts monolayers. After 5–7
days, trypomastigotes released in supernatant were collected by centrifugation for 15 min at
3300 rpm, re-suspended in DMEM and used to infect mice.
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Infection of mice
Swiss Webster male mice weighting 18–20 g were infected intraperitoneally with 104 blood-
stream trypomastigote form of T. cruzi Y parasites. For bioluminescence imaging, six week old
BALB/c male and female mice were infected by intraperitoneal injection with 103 T. cruzi CL-
luc trypomastigotes derived from cell culture supernatant.
Treatment strategies
All drugs were solubilized in 10% solutol and administered orally, b.i.d, at previously opti-
mized doses: 25 mg/kg for 9 and 12, 50 mg/kg for benznidazole, and 20 mg/kg for posacona-
zole. The treatment of Swiss mice acutely infected with T. cruzi Y strain was started with
parasitemia onset at 5 days post-infection (dpi). The treatment of BALB/c mice infected with
CL-luc parasites started at 14 dpi (acute phase), when parasitemia reached a peak as detected
by bioluminescence, or at 126 dpi (chronic phase), when a chronic state of infection was
established [46]. In all models, only parasite-positive mice (5 mice/group) were used in the
treatment course lasting for 28 days. To assess if sterile cure was achieved, immunossupres-
sion was performed in the chronic model of infection 4 weeks after the end of treatment,
with two doses of cyclophosphamide (200 mg/kg) by intraperitoneal (i.p.) injection at 3-day
intervals.
Parasitemia determination
In Swiss mice acutely infected with T. cruzi Y strain, parasites in the blood of each animal were
quantified by using the Pizzi-Brener method. The total number of parasites are counted in 50
fields under 400X magnification of freshly prepared blood samples (5 μl drops) obtained from
the tail veins of mice, collected 3 times a week, starting at 5 dpi and continued until the end of
treatment [70]. Mortality was monitored daily and % survival was calculated using GraphPad
prism software.
Bioluminescent imaging
BALB/c mice infected with parasites carrying a bioluminescent marker were imaged at 13 dpi,
before treatment was initiated, and then once a week, both during the 28-day treatment period
and 39 days post-treatment, as previously described [35]. Briefly, mice were injected i.p. with
150 mg/kg D-luciferin potassium salt in PBS (Gold Biotechnology, St. Louis, MO), and 5 min-
utes later, anesthetized by isofluorane inhalation (3–5%) and imaged using IVIS Lumina in
vivo imaging system (PerkinElmer, Waltham, MA) with 180s exposure time. Data acquisition
and analysis were performed with the LivingImage V4.1 software (PerkinElmer, Waltham,
MA). Uninfected controls were imaged in parallel to establish a negative threshold.
Ex-vivo imaging
To evaluate sites of parasite persistence in BALB/c mice infected with T. cruzi expressing lucif-
erase, we performed ex vivo imaging of selected internal organs according to the protocol
adapted from Lewis et al., 2014 [39]. Briefly, the animals were injected i.p. with 150 mg/kg of
D-luciferin, euthanized in a CO2 chamber and perfused with 10 ml of D-luciferin. Then, heart,
liver, kidneys, lungs, spleen, mesenteric fat, skeletal muscle (excised from left thigh) and the
whole gastro-intestinal (GI) tract were removed, placed in a petri dish with PBS containing
300 μg/ml of D-luciferin, and imaged using the IVIS Lumina system.
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Histology
Brain, heart, liver, kidney, GI tract and lungs from uninfected mice for toxicity analysis, and
heart and GI tract from infected animals were removed and fixed as described above. Samples
were processed for routine histologic examination in the Histology Core of Moore Cancer
Center (UCSD), embedded in paraffin, sectioned and stained with hematoxylin and eosin. The
slides were scanned using Nanozoomer Slide Scanner (Hamamatsu Photonics, NJ, USA) and
images were obtained through NDP viewer software (Hamamatsu Photonics, NJ, USA).
Histopathology analysis
To quantify levels of inflammation, 5 random images of mouse hearts (10× magnification)
were obtained from each animal, 5 animals/group. At this magnification, 5 fields comprise the
majority of the area of the heart section. Image processing was performed using Fiji software
[44], where cell nuclei was segmented through the Particle Analyzer plugin and the fraction of
total area of the image occupied by all cell nuclei was then measured. Even though cardiomyo-
cytes and cardiac fibroblasts cell nuclei are being counted together with inflammatory cells,
uninfected heart sections were used as controls and provide a baseline number.
Blood analysis
Terminal blood collection was performed via cardiac cavity exsanguination in uninfected and
T. cruzi-infected mice. Blood was collected in serum separator tubes (Microtainer, BD Biosci-
ences), allowed to clot for 0.5–2.0 h and then centrifuged for 90 s at 10000 g. Serum was
removed and analyzed at the Central Animal Facilities of the Oswaldo Cruz Foundation (Rio
de Janeiro, Brazil, CECAL/Fiocruz platform) using Vitros 250 (Ortho Clinical-Johnson &
Johnson), or at the UC Davis Comparative Pathology Laboratory (Davis, CA, USA), where
samples were analyzed using Roche Cobas Integra 400 Plus clinical chemistry analyzer. In
both facilities, tests were performed for electrolytes and enzyme metabolites indicative of liver,
kidney and cardiac functions, including alanine aminotransferase (ALT), aspartate amino-
transferase (AST), total bilirubin (BIL), albumin (ALB), alkaline phosphatase (ALP), blood
urea nitrogen (BUN), creatinine (CRE), urea, calcium, phosphorus, glucose, total protein.
Statistical analysis
Student’s t-test was used for evaluation of differences in experimental data between groups.
Values were considered statistically significant when p 0.05. Statistics were analyzed by
GraphPad Prism Software.
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